Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim Prophylaxis in Elderly Breast Cancer
NCT00117910Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2002
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pegfilgrastim in neutropenia (2 arms), sponsored by Amgen. Primary endpoint: Incidence of protocol defined neutropenic events in chemotherapy cycle 1 at Cycle 1. Started Oct 2002; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT00117910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117910.